Abstract
Matrix metalloproteinases have been shown to be important in tumour invasion and metastasis, and the use of matrix metalloproteinase inhibitors in animal models has suggested that these agents may be useful in the control of malignant disease. This article reports the results of an early clinical trial of batimastat, one of the first generation of metalloproteinase inhibitors, in patients with malignant ascites. The drug was well absorbed via the intraperitoneal route and associated with few side-effects. Furthermore, a response to treatment was seen in about half the evaluable patients with advanced malignant disease. The results suggest that further research on the use of matrix metalloproteinase inhibitors in patients with malignant disease is worthwhile.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacokinetics*
-
Ascites / drug therapy
-
Ascites / etiology*
-
Ascites / metabolism*
-
Gastrointestinal Neoplasms / complications
-
Gastrointestinal Neoplasms / metabolism*
-
Humans
-
Infusions, Parenteral
-
Metalloendopeptidases / antagonists & inhibitors*
-
Middle Aged
-
Phenylalanine / administration & dosage
-
Phenylalanine / analogs & derivatives*
-
Phenylalanine / pharmacokinetics
-
Protease Inhibitors / administration & dosage
-
Protease Inhibitors / pharmacokinetics*
-
Thiophenes / administration & dosage
-
Thiophenes / pharmacokinetics*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Protease Inhibitors
-
Thiophenes
-
Phenylalanine
-
batimastat
-
Metalloendopeptidases